Dosing & Uses
Dosage Forms & Strengths
nasal spray
- 2mg/mL
Endometriosis
1 spray (200 mcg/spray) in one nostril qAM, 1 spray in the other nostril qPM (total 400 mcg/day) on days 2-4 of menstrual cycle (2 sprays/day)
May increase to 800 mcg/day if still menstruating after 2 month: 1 spray in each nostril twice daily
Maximum treatment duration: 6 months
Dosage Forms & Strengths
nasal spray
- 200mcg/spray
Central Precocious Puberty
<2 years: Safety and efficacy not established
≥2 years: 2 sprays (200 mcg/spray) in each nostril twice daily (total 1600 mcg/day)
May increase to 1800 mcg/day: 3 sprays (200 mcg/spray) into alternating nostrils TID (total 9 sprays/day)
Discontinue when puberty onset is desired
Adverse Effects
1-10%
Acne (10%)
Breast enlargement (8%)
Vaginal bleeding (8%)
Seborrhea (3%)
Emotional lability (6%)
Vaginal discharge (3%)
Rhinitis (5%)
Body odor (4%)
Increase in pubic hair (5%)
Frequency Not Defined
Arthralgia
Breast engorgement
Chloasma
Maculopapular rash
Paresthesia
Weakness
Palpitation
Eye pain
Postmarketing Reports
Liver injury
Pituitary apoplexy
Seizures
Pituitary gland changes
Liver injury (rare)
Ovarian hyperstimulation syndrome
Psychiatric Disorders: Emotional lability, including crying, irritability, impatience, anger, and aggression; depression, including rare reports of suicidal ideation and attempt, in children treated for central precocious puberty
Warnings
Contraindications
Pregnancy, hypersensitivity, lactation, undiagnosed abnormal vaginal bleeding
Cautions
Goal in adult females is to suppress menstruation; max treatment period 6 mth
May cause increase in bone turnover & decrease in bone mineral content
Ovarian cysts may develop within first 2 months of therapy and occur more commonly in women with polycystic ovarian disease
Cases of pituitary apoplexy reported
Use caution in patients with risk factors for decreased bone mineral density
Irregular or incomplete daily doses may result in stimulation of the pituitary-gonadal axis; counsel caregivers to assure full compliance
During first month of treatment, may initially expect some signs of puberty, e.g., vaginal bleeding or breast enlargement, may occur; such changes should resolve soon after first month; if such resolution does not occur within first two months of treatment, this may be due to lack of compliance or presence of gonadotropin independent sexual precocity; if both possibilities excluded, the dose omay be increased to 1800 mcg/day administered as 600 mcg tid
Patients with intercurrent rhinitis should consult their physician for use of topical nasal decongestant; if use of topical nasal decongestant required during treatment decongestant should not be used until at least 2 hr after administering therapy; sneezing during or immediately after administering therapy should be avoided, if possible, since may impair drug absorption
Convulsions reported in patients receiving GnRH agonists; reports with GnRH agonists have included patients with a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and patients on concomitant medications that have been associated with convulsions such as bupropion and SSRIs; convulsions also reported in patients in the absence of any of the conditions listed
Psychiatric events reported in patients taking GnRH agonists; postmarketing reports with this class of drugs include symptoms of emotional lability, such as crying, irritability, impatience, anger, and aggression; monitor for development or worsening of psychiatric symptoms during treatment
Pregnancy & Lactation
Pregnancy Category: X
Lactation: Excretion in milk unknown, contraindicated
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Synthetic decapeptide that is an agonist of LHRH, desensitizes response to endogenous GnRH, which in turn reduces secretion of LH and FSH and subsequently causes decreased ovarian and testicular production
Pharmacokinetics
Peak serum time: 10-45 min
Protein Bound: 78-84%
Metabolism: Degraded by peptidase
Metabolites: Dipeptide, tripeptide, pentapeptide, hexapeptide amide, D-naphthylalanine, 2-naphthylacetic acid (inactive)
Excretion: Urine (44-55%); feces (19-44%)
Half-Life: 3 hr
Bioavailability (1-6%)
Onset: 1 month (initial effect)
Peak effect: 12 wk (endometriosis); 4-8 hr (gonadotropin secretion stimulation)
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.